Sign Up
Stories
Advancing ALS Treatment through Protein Research
Share
Advancements in Huntington's Disease Tre...
Neurodegenerative Disease Market Expansi...
Phase 2 Trial for Promising Alzheimer's ...
4DMT Presents Positive Interim Data
AMX0035 for PSP: Phase 3 Trial Commences
ARMGO Pharma's Positive Trial Results
Overview
API
ProMIS Neurosciences reveals insights on misfolded proteins in neurodegenerative diseases and the potential ALS treatment.
Ask a question
How could these molecular pathology insights impact the broader field of neurodegenerative disease research and treatment?
How might targeting misfolded proteins revolutionize the treatment of other neurodegenerative diseases?
What further research or trials are needed to advance the development of PMN267 for ALS treatment?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage